Who are Gemcitabine hydrochloride for injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cladribine Low Dose, BICTEGRAVIR SODIUM, Biktarvy, Pifeltro, Vemlidy, Lonsurf.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gemcitabine-hydrochloride-for-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Gemcitabine hydrochloride for injection — Competitive Intelligence Brief

Gemcitabine hydrochloride for injection (Gemcitabine hydrochloride for injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside analog; antimetabolite. Area: Oncology.

phase 3 Nucleoside analog; antimetabolite Ribonucleotide reductase; DNA synthesis Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Gemcitabine hydrochloride for injection (Gemcitabine hydrochloride for injection) — Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing chain termination and cell death.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Gemcitabine hydrochloride for injection TARGET	Gemcitabine hydrochloride for injection	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	phase 3	Nucleoside analog; antimetabolite	Ribonucleotide reductase; DNA synthesis
Cladribine Low Dose	Cladribine Low Dose	Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany	phase 3	Purine nucleoside analog	Ribonucleotide reductase; DNA synthesis
BICTEGRAVIR SODIUM	BICTEGRAVIR SODIUM		marketed	Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]		2018-01-01
Biktarvy	BICTEGRAVIR	Gilead Sciences	marketed	Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]		2018-01-01
Pifeltro	DORAVIRINE	Merck & Co.	marketed	Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]		2018-01-01
Vemlidy	TENOFOVIR ALAFENAMIDE	Gilead Sciences	marketed	Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]		2015-01-01
Lonsurf	TIPIRACIL	Taiho Oncology Inc	marketed	Nucleoside Analog Antiviral [EPC]	Thymidine phosphorylase	2015-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-09-22 — Lonsurf · RE46284 · US
2032-08-15 — Biktarvy · 8754065 · US
2032-08-15 — Biktarvy · 9296769 · US
2033-02-15 — Biktarvy · 8754065*PED · US
2033-02-15 — Biktarvy · 9296769*PED · US
2033-12-19 — Biktarvy · 9216996 · US
2033-12-19 — Biktarvy · 9732092 · US
2034-06-17 — Lonsurf · 10457666 · US
2034-06-17 — Lonsurf · 9527833 · US
2034-09-05 — Lonsurf · 9943537 · US
2035-06-19 — Biktarvy · 9708342 · US
2035-06-19 — Biktarvy · 10385067 · US
2036-11-08 — Biktarvy · 10548846 · US
2037-02-03 — Lonsurf · 10960004 · US
2037-02-03 — Lonsurf · 10456399 · US

Sponsor landscape (Nucleoside analog; antimetabolite class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Astellas Pharma Global Development, Inc. · 1 drug in this class
AstraZeneca · 1 drug in this class
Celgene · 1 drug in this class
Centre Hospitalier Universitaire Dijon · 1 drug in this class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · 1 drug in this class
Eisai Inc. · 1 drug in this class
Gruppo Italiano Malattie EMatologiche dell'Adulto · 1 drug in this class
Jiangsu Simcere Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Gemcitabine hydrochloride for injection — Competitive Intelligence Brief. https://druglandscape.com/ci/gemcitabine-hydrochloride-for-injection. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab